FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 白花油國際有限公司 (於百慕達註冊成立之有限公司) 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00239 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 600,000,000 | HKD | | 0.05 | HKD | | 30,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | | | 本月底結存 | | | 600,000,000 | HKD | | 0.05 | HKD | | 30, ...

根据白花油此前发布的截至2025年6月30日止6个月中期业绩，该集团取得收入9473.4万港元，同比减少 28.5%；报告溢利3974.3万港元，同比减少16.2%；基础经常性溢利4529.4万港元，同比减少26.6%；报 告溢利每股盈利12.8港仙，拟派发中期股息每股3港仙及特别中期股息每股5港仙。 香港联交所最新资料显示，1月2日，白花油(00239)股东将股票由USB Securities Hong Kong Limited转入 香港上海汇丰银行，转仓市值3823.61万港元，占比5.18%。 ...

智通财经APP获悉，香港联交所最新资料显示，1月2日，白花油(00239)股东将股票由USB Securities Hong Kong Limited转入香港上海汇丰银行，转仓市值3823.61万港元，占比5.18%。 根据白花油此前发布的截至2025年6月30日止6个月中期业绩，该集团取得收入9473.4万港元，同比减少 28.5%；报告溢利3974.3万港元，同比减少16.2%；基础经常性溢利4529.4万港元，同比减少26.6%；报 告溢利每股盈利12.8港仙，拟派发中期股息每股3港仙及特别中期股息每股5港仙。 ...

Key Points - As of December 19, 38 stocks reached their 52-week highs, with Li Gao Health Life (02370), Ginkgo Education (01851), and Kangqiao Yuelife (02205) leading the high rate at 36.36%, 18.72%, and 8.70% respectively [1] - The top three stocks that achieved new highs are as follows: - Li Gao Health Life (02370) closed at 0.670, with a peak of 0.750, marking a 36.36% increase - Ginkgo Education (01851) closed at 2.430, with a peak of 2.600, marking an 18.72% increase - Kangqiao Yuelife (02205) closed at 1.200, with a peak of 1.250, marking an 8.70% increase [1] - Other notable stocks that reached new highs include Liangqing Holdings (1,000) at 7.14%, Jinxing International Holdings (02307) at 7.04%, and Wuxi Life (08148) at 6.21% [1] 52-Week Low Summary - The 52-week low rankings show that Haowen Holdings (08019) had the largest decline at -16.13%, closing at 0.130 [2] - Other significant declines include NIU Holdings (08619) at -11.86%, closing at 0.156, and Hashkey HLDGS (03887) at -9.59%, with a low of 5.090 [2] - Additional stocks with notable declines include Songdu Service (09608) at -9.09%, closing at 0.068, and Ruike Bio-B (02179) at -5.41%, closing at 5.070 [2]

Core Viewpoint - Xinfeng Pharmaceutical is facing legal challenges as it has been prosecuted for alleged unit bribery, which may adversely affect its brand reputation and future business development [1][3][5]. Group 1: Legal Issues - On December 10, Xinfeng Pharmaceutical announced that it has been prosecuted for alleged unit bribery, with the prosecution materials received from the supervisory committee [1][3]. - The company is currently in the prosecution review stage and has appointed defense lawyers to handle the case [5]. Group 2: Stock Market Reaction - Following the announcement of the legal issues, Xinfeng Pharmaceutical's stock price experienced a significant increase, reaching a limit-up of 4.15 yuan per share, with a total market capitalization of 8.067 billion yuan [2]. Group 3: Company Performance - For the first three quarters of the year, Xinfeng Pharmaceutical reported a revenue of 4.266 billion yuan, a year-on-year decrease of 6.55%, and a net profit attributable to shareholders of 152 million yuan, down 13.74% year-on-year [8]. - The company's financial performance has been unstable, with a projected decline of over 60% in net profit attributable to shareholders for 2024 [8].

Core Viewpoint - Xinfeng Pharmaceutical is facing legal challenges as it has been prosecuted for alleged corporate bribery, which may negatively impact its brand reputation and future business development [2][3][5]. Group 1: Legal Issues - On December 10, Xinfeng Pharmaceutical announced that it has received materials for prosecution regarding alleged corporate bribery from the procuratorial organ [2][3]. - The company is currently in the prosecution review stage and will cooperate with relevant authorities while appointing defense lawyers for the case [5]. Group 2: Financial Performance - For the first three quarters of this year, Xinfeng Pharmaceutical reported revenue of 4.266 billion yuan, a year-on-year decrease of 6.55% [8]. - The net profit attributable to shareholders was 152 million yuan, down 13.74% year-on-year, with projections indicating a more than 60% decline in net profit for 2024 [8]. Group 3: Company Background - Xinfeng Pharmaceutical is primarily engaged in pharmaceutical manufacturing, including traditional Chinese medicine cultivation, new drug research and development, production, and sales, focusing on cardiovascular and digestive system products [8]. - The company has faced negative news in recent years, including a bribery case involving its subsidiary, Guizhou Keka Pharmaceutical Co., Ltd., which is 99.99% owned by Xinfeng Pharmaceutical [6].

信邦制药表示，该事项可能对公司品牌声誉、业务拓展及未来发展产生不利影响。目前案件处于审查起诉阶段，最终结果以司法机关出具的法律文书为 准。 值得关注的是，10日上午临近收盘时，信邦制药股价突然异动拉升，并迅速封至涨停。截至当日收盘，公司股价为4.15元/股，总市值为80.67亿元。 12月10日晚间，信邦制药（002390）公告称，公司近日收到检察机关《审查起诉阶段委托辩护人/申请法律援助告知书》《犯罪嫌疑人诉讼权利义务告知 书》，对公司涉嫌单位行贿一案，检察机关已收到监察委员会移送起诉的材料。 | 信邦制药 | | | | --- | --- | --- | | 002390 國 深股通 LT ▼ | | | | 今开 3.78 最高 4.15 最低 4.15 | | 3.76 | | 10.08% 0.38 换手☺ 7.64% 总手 147.3万 金额 6.03亿 | | | | 总值⊙ 80.67亿 流值 80.00亿 市盈 ~⊙ 39.72 | | 更多 | | ◀ Al异动解读:中药新规强化行业壁垒+公司 ... | | | | 分时 五日 月K | 曲名 | | | 均价:4.10 最新:4.15 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 12月10日晚间，信邦制药（002390）公告称，公司近日收到检察机关《审查起诉阶段委托辩护人/申请 法律援助告知书》《犯罪嫌疑人诉讼权利义务告知书》，对公司涉嫌单位行贿一案，检察机关已收到监 察委员会移送起诉的材料。 信邦制药表示，该事项可能对公司品牌声誉、业务拓展及未来发展产生不利影响。目前案件处于审查起 诉阶段，最终结果以司法机关出具的法律文书为准。 值得关注的是，10日上午临近收盘时，信邦制药股价突然异动拉升，并迅速封至涨停。截至当日收盘， 公司股价为4.15元/股，总市值为80.67亿元。 行贿案源自一起并购 信邦制药此次被起诉，并非毫无征兆。 根据贵州省"开阳县人民法院"发布的消息，2025年2月26日，开阳县人民法院立案受理贵州科开医药有 限公司（下称"科开医药"）单位行贿罪、安怀略行贿罪一案。 公开资料显示，科开医药由信邦制药控股99.99%，安怀略则是信邦制药原董事长，后于2022年4月辞 职，其女安吉随后接任董事长一职。 3月3日晚间，信邦制药发布关于控股子公司涉及诉 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 白花油國際有限公司 (於百慕達註冊成立之有限公司) 呈交日期: 2025年12月1日 第 2 頁 共 10 頁 v 1.1.1 FF301 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00239 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 311,640,000 | | 0 | | 311,640,000 | | 增加 / 減少 (-) | | | 0 | | 0 | | | | 本月底結存 | | | 311,640,000 | | 0 | | 311,640,000 | | 1. 股份分類 ...

Core Viewpoint - The company, Dream洁股份, has issued a statement addressing malicious and false information spread by its board member, Chen Jie, which has severely damaged the company's reputation and market image [2][5]. Group 1: Company Response - Dream洁股份 has reported that Chen Jie, using her position as a board member, disseminated false statements that have harmed the reputation of the company and its executives, disrupted capital market order, and misled investors [5]. - The company has filed a report with the public security authorities and is pursuing legal action against Chen Jie for fabricating and spreading false information, seeking to stop the infringement, eliminate the impact, publicly apologize, and compensate for losses [5][6]. Group 2: Background of the Dispute - The dispute originates from a share transfer transaction that took place three years ago, involving major shareholders transferring a total of 77 million shares to Changsha Jinsen at a price of 5 yuan per share, totaling 385 million yuan [8][10]. - Following the share transfer, Changsha Jinsen became the largest shareholder with voting rights in Dream洁股份, although issues regarding the authenticity of information disclosure and funding sources have arisen [10][11]. Group 3: Recent Developments - In August 2023, Dream洁股份 announced that the voting rights agreement with Changsha Jinsen would be terminated in August 2025, leading to a change in control of the company, with major shareholder Jiang Tianwu regaining voting rights [11][12]. - The company has recently received a regulatory notice requiring it to correct two major violations related to revenue recognition and financial management practices, resulting in warnings issued to key executives [13][16].